Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In West To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in West between February 16, 2023, and February 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , June 6, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against West Pharmaceutical Services, Inc. ("West" or …

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast prese.

AIEV Received Approval to Trade on the OTCQB Venture Market effective June 5, 2025 WILMINGTON, Del. , June 6, 2025 /PRNewswire/ -- Thunder Power Holdings, Inc. (OTCQB: AIEV) ("Thunder Power" or the "Company"), a technology innovator and developer of premium passenger Electric Vehicles ("EVs") whose acquisition strategy is focused on addressing strategic gaps in the EV sector with a diversified approach across the clean energy value chain, today provided listing and operational updates.

Nvidia Corporation's momentum is stronger than what I initially anticipated. I reaffirm my Strong Buy rating after spectacular growth results, even with the tariff drama, the DeepSeek fears, and the new export restrictions. Despite an $8B headwind, Nvidia guides for 50% YoY revenue growth next quarter, with potential upside from an upcoming export-compliant AI chip, the B30.

Investors need to pay close attention to GIS stock based on the movements in the options market lately.

FERG made it to the Zacks Rank #1 (Strong Buy) income stocks list on June 6, 2025.

TTD stock has plunged 47% in six months amid rising costs, macro pressure, and a shaky digital ad market outlook.

SO's PowerSecure expands its alliance with Edged to deliver ultra-efficient, AI-ready data centers across key U.S. markets.

NOMD lifts gross margins despite soft sales, betting big on bold frozen food innovations to fuel its growth strategy.

FuelCell Energy (FCEL) came out with a quarterly loss of $1.79 per share versus the Zacks Consensus Estimate of a loss of $1.51. This compares to loss of $2.10 per share a year ago.

When you buy coffee, book a flight, or shop online, there's a good chance Visa Inc. NYSE: V is working for you behind the scenes. This financial technology (fintech) titan operates one of the planet's largest electronic payment networks.

– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D.

Lululemon dropped over 22% following a guidance cut and tariff-related worries. Lululemon can't control tariffs, but it can innovate its way back to the top.

The MSTY ETF features an annual yield that's hard for income-focused investors to resist.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options

The pipeline stocks are a great place to get dividends (yield and growth) at a nice discount.

PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today spotlights the efforts of Ellen Kim, M.D., Lead Principal Investigator for the Company's Phase 3 FLASH (1 and 2) studies in early stage cutaneous T-cell lymphoma (CTCL), in advancing HyBryte™ (synthetic hypericin) as a potential new therapy for patients living with mycosis fungoides (MF), the most common form of CTCL.

US Department of Labor today contradicts a downbeat ADP report earlier in the week, and shows jobs employment grew in May.

Scotts Miracle-Gro reaffirms its fiscal 2025 outlook as strong seasonal demand and retailer restocking boost confidence.

CYBR gains ground on PANW with standout earnings, AI-powered tools and expanding market reach.